News zum Sektor Gesundheit aus China

 

3SBIO (01530.HK) announced that it repurchased 1 million shares on Oct 12 at prices ranging from HKD14.7 to HKD14.9 per share, involving approximately HKD14.8 million.Since the repurchase mandate resolution was passed, the group has cumulatively repurchased 22.963 million shares, accounting for 0.91% of its issued shares. (su)~A......

HKEX (00388.HK) announced that it will add 12 single stock option classes on November 9, covering KINGBOARD HLDG (00148.HK), ASMPT (00522.HK), KB LAMINATES (01888.HK), CHINAGOLDINTL (02099.HK), CSOP HS TECH (03033.HK), HANSOH PHARMA (03692.HK), GIGADEVICE (03986.HK), BIREN TECH (06082.HK), CIG (06166.HK), MONTAGE TECH (06809.HK)......

LEADS BIOLABS-B (09887.HK) announced that its core product Vilastobart (Opretisumab, a PD-L1/4-1BB bispecific antibody) has received Fast Track designation from the US FDA for the first-line treatment of advanced biliary tract cancer (BTC). This marks the second FDA Fast Track designation obtained by the product following extrap......

YIDU TECH (02158.HK) announced that it entered into a secured loan product provided by Goldman Sachs on May 26 last year, involving a loan amount of USD65 million. The transaction constituted a discloseable transaction and also constituted an advance to an entity, but the company failed to publish an announcement for the transac......

EDDING GENOR (06998.HK) announced that the Investigational New Drug (IND) application for a Phase II clinical trial of its highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific antibody GB268 in combination with chemotherapy as a first-line treatment for unresectable locally advanced or metastatic colorectal adenocar......

Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors Second FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors...

3SBIO (01530.HK) announced that it repurchased 2.5 million shares last Friday (9th) at prices ranging from HKD14.98 to HKD15.18 per share, involving approximately HKD37.588 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the authori......

ICP-B161 delivers an extended half‑life, which allows for less frequent dosing and supports subcutaneous administration....

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in......

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the positive 52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. (Ascletis) in China, along with mechanistic data, will be presented at the 2026 Fall Clinical Dermatology Conference taking place October 8-11, in Las Vegas, Nevada. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 in China where it holds an exclusive license to denifanstat, and by Sagimet in the rest of the world....

How quality, supply resilience, manufacturing excellence and innovation are supporting the next generation of biologics. MILAN, Oct. 9, 2026 /PRNewswire/ -- Europe's biologics sector is expanding as ageing populations and the rising burden of chronic, autoimmune and rare diseases increase......

SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines Appointments support continued advancement of Everest's mRNA......

3SBIO (01530.HK) announced that it repurchased 1.7 million shares yesterday (8 Oct), at a price ranging from HKD15.4 to HKD15.75 per share, involving approximately HKD26.5 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the authorit......

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISCO and SUZHOU, China, Oct. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")......

TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares......

HENGRUI PHARMA (01276.HK) announced that it received notification from the European Medicines Agency (EMA), formally confirming and accepting the marketing authorization application submitted by the company for Fluzoparib Capsules. This marks the second self-developed innovative drug by the company to submit a listing applicatio......

SHANDONG XINHUA (00719.HK) announced that its product Sacubitril Valsartan Sodium Tablets recently obtained a drug registration certificate approved and issued by the National Medical Products Administration. The prescription drug is used for adult patients with chronic heart failure with reduced ejection fraction to reduce the ......

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term......

"You've Got Mail": China Got Its Hands On F-35 Stealth Parts Because A UPS Worker Missed An Email Forget hackers, honey traps and photon-counting lasers. China's latest haul of F-35 secrets apparently came courtesy of an unread email. According to a new Bloomberg report, the F-35 cockpit canopy and weapons-bay door that ended up in Beijing's possession were routed through Hong Kong because a United Parcel Service (UPS) employee missed an email warning not to send the shipment through Hong Kong. The email, from freight forwarder DSV (working on behalf of Lockheed Martin ), said the parts must not transit certain countries under the US International Traffic in Arms Regulations (ITAR), the rules designed precisely to keep American weapons tech away from American adversaries. Regular readers will recall that we have been following this saga since it first went "MIA" on the way to Hong Kong last month. What started as a mysterious detour has now been traced to the most munda...